Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lif...
Saved in:
| Published in: | Circulation Cardiovascular quality and outcomes Vol. 15; no. 6; p. 101161CIRCOUTCOMES121008552 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.06.2022
|
| Subjects: | |
| ISSN: | 1941-7705, 1941-7705 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lifetime can reduce the risk of cardiovascular disease by more than half. However, these findings have not been replicated in randomized clinical trials, and the effect of treatment duration on the magnitude of risk reduction remains uncertain. The aim of this article was to evaluate the relationship between lipid-lowering drug exposure time and relative risk reduction of major cardiovascular events in randomized clinical trials.
We conducted a systematic review and meta-analysis of randomized clinical trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors that report LDL-C levels and effect sizes for each year of follow-up. The primary end point was major vascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. Hazard ratios during each year of follow-up were meta-analyzed using random-effects models.
A total of 21 trials with 184 012 patients and an average mean follow-up of 4.4 years were included. Meta-regression showed there was greater relative risk reduction in major vascular events with increasing duration of treatment (
<0.001). For example, each mmol/L LDL-C lowered was associated with a relative risk reduction in major vascular events of 12% (95% CI, 8%-16%) for year 1, 20% (95% CI, 16%-24%) for year 3, 23% (95% CI, 18%-27%) for year 5, and 29% (95% CI, 14%-42%) for year 7.
The benefits of LDL-C lowering do not seem to be fixed but increase steadily with longer durations of treatment. The results from short-term randomized trials are compatible with the very strong associations between LDL-C and cardiovascular events seen in Mendelian randomization studies. |
|---|---|
| AbstractList | Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lifetime can reduce the risk of cardiovascular disease by more than half. However, these findings have not been replicated in randomized clinical trials, and the effect of treatment duration on the magnitude of risk reduction remains uncertain. The aim of this article was to evaluate the relationship between lipid-lowering drug exposure time and relative risk reduction of major cardiovascular events in randomized clinical trials.
We conducted a systematic review and meta-analysis of randomized clinical trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors that report LDL-C levels and effect sizes for each year of follow-up. The primary end point was major vascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. Hazard ratios during each year of follow-up were meta-analyzed using random-effects models.
A total of 21 trials with 184 012 patients and an average mean follow-up of 4.4 years were included. Meta-regression showed there was greater relative risk reduction in major vascular events with increasing duration of treatment (
<0.001). For example, each mmol/L LDL-C lowered was associated with a relative risk reduction in major vascular events of 12% (95% CI, 8%-16%) for year 1, 20% (95% CI, 16%-24%) for year 3, 23% (95% CI, 18%-27%) for year 5, and 29% (95% CI, 14%-42%) for year 7.
The benefits of LDL-C lowering do not seem to be fixed but increase steadily with longer durations of treatment. The results from short-term randomized trials are compatible with the very strong associations between LDL-C and cardiovascular events seen in Mendelian randomization studies. Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lifetime can reduce the risk of cardiovascular disease by more than half. However, these findings have not been replicated in randomized clinical trials, and the effect of treatment duration on the magnitude of risk reduction remains uncertain. The aim of this article was to evaluate the relationship between lipid-lowering drug exposure time and relative risk reduction of major cardiovascular events in randomized clinical trials.BACKGROUNDMendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lifetime can reduce the risk of cardiovascular disease by more than half. However, these findings have not been replicated in randomized clinical trials, and the effect of treatment duration on the magnitude of risk reduction remains uncertain. The aim of this article was to evaluate the relationship between lipid-lowering drug exposure time and relative risk reduction of major cardiovascular events in randomized clinical trials.We conducted a systematic review and meta-analysis of randomized clinical trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors that report LDL-C levels and effect sizes for each year of follow-up. The primary end point was major vascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. Hazard ratios during each year of follow-up were meta-analyzed using random-effects models.METHODSWe conducted a systematic review and meta-analysis of randomized clinical trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors that report LDL-C levels and effect sizes for each year of follow-up. The primary end point was major vascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. Hazard ratios during each year of follow-up were meta-analyzed using random-effects models.A total of 21 trials with 184 012 patients and an average mean follow-up of 4.4 years were included. Meta-regression showed there was greater relative risk reduction in major vascular events with increasing duration of treatment (P<0.001). For example, each mmol/L LDL-C lowered was associated with a relative risk reduction in major vascular events of 12% (95% CI, 8%-16%) for year 1, 20% (95% CI, 16%-24%) for year 3, 23% (95% CI, 18%-27%) for year 5, and 29% (95% CI, 14%-42%) for year 7.RESULTSA total of 21 trials with 184 012 patients and an average mean follow-up of 4.4 years were included. Meta-regression showed there was greater relative risk reduction in major vascular events with increasing duration of treatment (P<0.001). For example, each mmol/L LDL-C lowered was associated with a relative risk reduction in major vascular events of 12% (95% CI, 8%-16%) for year 1, 20% (95% CI, 16%-24%) for year 3, 23% (95% CI, 18%-27%) for year 5, and 29% (95% CI, 14%-42%) for year 7.The benefits of LDL-C lowering do not seem to be fixed but increase steadily with longer durations of treatment. The results from short-term randomized trials are compatible with the very strong associations between LDL-C and cardiovascular events seen in Mendelian randomization studies.CONCLUSIONSThe benefits of LDL-C lowering do not seem to be fixed but increase steadily with longer durations of treatment. The results from short-term randomized trials are compatible with the very strong associations between LDL-C and cardiovascular events seen in Mendelian randomization studies. |
| Author | Wang, Nelson Woodward, Mark Huffman, Mark D Rodgers, Anthony |
| Author_xml | – sequence: 1 givenname: Nelson orcidid: 0000-0002-8197-5090 surname: Wang fullname: Wang, Nelson organization: The George Institute for Global Health, School of Public Health Imperial College, London, United Kingdom (M.W., A.R.) – sequence: 2 givenname: Mark orcidid: 0000-0001-9800-5296 surname: Woodward fullname: Woodward, Mark organization: Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.) – sequence: 3 givenname: Mark D orcidid: 0000-0001-7412-2519 surname: Huffman fullname: Huffman, Mark D organization: Feinberg School of Medicine, Departments of Preventive Medicine and Medicine, Northwestern University, Chicago, IL (M.D.H.) – sequence: 4 givenname: Anthony surname: Rodgers fullname: Rodgers, Anthony organization: The George Institute for Global Health, School of Public Health Imperial College, London, United Kingdom (M.W., A.R.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35430872$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkN1OAjEQhRuDUUFfQXvpzWLb3e6Pd7hBJYGQKFyT0k6lZrfFdhfCK_jULhETr2Zy5jsnOdNHPessIHRHyZDSlD6Uk7dyvlyU89n4fUgZHRKSc87O0BUtEhplGeG9f_sl6ofwSUgaszS-QJcxT2KSZ-wKfZeu3rrWKmM_8BNY0KYJ2GlcblwFoQHvqmjq9uCPwGIDXmwPWDuPmw3gN1CtbIyzR8dMfHZyKbwybieCbCvh8XgHtgmP-P3QZdWiMbIz7QzssbAKz6AR0ciK6hBMuEbnWlQBbk5zgJbP40X5Gk3nL5NyNI1kwpI0yhOtY5kIneZrsmY5AcU51yBVClRRyRlVBRMkFiwrMpbrgnRq3B1TmWXrgg3Q_W_u1ruvtuu4qk2QUFXCgmvDiqWcEVZ0yR16e0LbdQ1qtfWmFv6w-vsf-wEYWHhm |
| CitedBy_id | crossref_primary_10_1016_j_ahj_2024_05_002 crossref_primary_10_1186_s12933_025_02816_3 crossref_primary_10_1111_eci_14269 crossref_primary_10_1177_17539447241277402 crossref_primary_10_1186_s12916_024_03407_x crossref_primary_10_17816_CS676903 crossref_primary_10_1093_eurheartj_ehad831 crossref_primary_10_1016_j_pcd_2024_05_003 crossref_primary_10_1017_S0029665122002750 crossref_primary_10_1186_s12944_024_02399_0 crossref_primary_10_3390_endocrines5020009 crossref_primary_10_1016_j_jacc_2025_06_006 crossref_primary_10_1007_s11883_023_01186_z crossref_primary_10_1093_cvr_cvaf045 crossref_primary_10_1007_s11886_024_02174_8 crossref_primary_10_1056_NEJMoa2415820 crossref_primary_10_1097_MOL_0000000000000868 crossref_primary_10_1007_s11883_023_01145_8 crossref_primary_10_1124_jpet_123_001878 crossref_primary_10_1016_j_jacadv_2024_101109 crossref_primary_10_3310_RLDH7432 crossref_primary_10_1016_j_ajpc_2023_100604 crossref_primary_10_1016_j_ijcrp_2025_200468 crossref_primary_10_1016_j_jacc_2024_03_402 crossref_primary_10_1161_CIRCULATIONAHA_122_061727 crossref_primary_10_15829_1560_4071_2024_6038 crossref_primary_10_3390_medicina61081484 crossref_primary_10_1097_MCA_0000000000001395 crossref_primary_10_1093_ckj_sfad089 crossref_primary_10_1097_MOL_0000000000001008 crossref_primary_10_3389_fpsyt_2023_1274648 crossref_primary_10_1161_CIR_0000000000001209 crossref_primary_10_1016_j_jacc_2025_04_043 crossref_primary_10_1016_j_pcad_2024_05_004 crossref_primary_10_1161_CIR_0000000000001303 crossref_primary_10_1097_HJH_0000000000003855 crossref_primary_10_1016_j_ajpc_2025_101303 crossref_primary_10_1136_bmj_o2939 crossref_primary_10_1161_JAHA_122_025737 crossref_primary_10_15829_1560_4071_2024_6148 crossref_primary_10_1007_s10557_022_07413_0 crossref_primary_10_1093_jalm_jfae048 crossref_primary_10_1016_j_ajpc_2022_100450 crossref_primary_10_1016_j_jacl_2023_05_098 crossref_primary_10_1016_j_jacadv_2024_100886 crossref_primary_10_1124_jpet_123_001963 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1161/CIRCOUTCOMES.121.008552 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1941-7705 |
| ExternalDocumentID | 35430872 |
| Genre | Journal Article |
| GroupedDBID | --- .XZ .Z2 0R~ 18M 29B 53G 5GY 5VS AAAAV AAHPQ AAIQE AAJCS AARTV AASCR AAWTL ABASU ABBUW ABDIG ABJNI ABPXF ABVCZ ABXVJ ABXYN ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADBBV ADGGA ADHPY AEBDS AFBFQ AFDTB AFEXH AFNMH AHQNM AHQVU AHVBC AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BQLVK C45 DIK DIWNM E3Z EBS EEVPB EX3 F5P FCALG FL- GNXGY GQDEL HLJTE HZ~ IKREB IN~ KD2 KQ8 KQB L-C NPM O9- ODMTH ODZKP OHYEH OK1 OPUJH OVD OVDNE OXXIT P2P P6G RAH RLZ S4S TEORI TR2 TSPGW V2I W2D W3M W8F WOW 7X8 ACBKD ADKSD |
| ID | FETCH-LOGICAL-c4246-84ff3c4af68b0b280ed555fecd6e1d1c521d92a03a279728f90d1c36e16c77b92 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000812359000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1941-7705 |
| IngestDate | Sun Nov 09 14:18:25 EST 2025 Mon Jul 21 05:14:22 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | coronary disease cholesterol clinical trials ezetimibe myocardial infarction |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4246-84ff3c4af68b0b280ed555fecd6e1d1c521d92a03a279728f90d1c36e16c77b92 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-8197-5090 0000-0001-7412-2519 0000-0001-9800-5296 |
| PMID | 35430872 |
| PQID | 2652029280 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2652029280 pubmed_primary_35430872 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-June-01 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-June-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation Cardiovascular quality and outcomes |
| PublicationTitleAlternate | Circ Cardiovasc Qual Outcomes |
| PublicationYear | 2022 |
| SSID | ssj0063263 |
| Score | 2.5236533 |
| Snippet | Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 101161CIRCOUTCOMES121008552 |
| Title | Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35430872 https://www.proquest.com/docview/2652029280 |
| Volume | 15 |
| WOSCitedRecordID | wos000812359000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAaTdP0ES-iZUXBrqIr7G1J0wQUadWu_gh_tTNtV_EgCF5ySBtok-nky8z0-wg5yOCAZrXSzDNZzKTjnGVZBg3AZWk8aX1bq5ZcRf1-PByqmzbgVrVllROfWDvqvDQYIz8SYQDndCVifvL8wlA1CrOrrYTGNOn4AGXQqqPhVxYhBGhSF9gr6QGK5EFb3wUg5yi5vE2u7wfJddq7Q4aFw7pgS_yOM-v95nzxv0-6RBZapElPG9NYJlO2WCFzaZtLXyUf6ApQVAk2L3oGLs89jCtaOpqgZC7yJ5RP7ApF1PCGQcM-QAHjUsCM9BYpX3FRcUSqH6E7-VHaSntYSVkd07svrmjaJCKoLnKa2rFmE0aUNXJ_3hskF6xVZmBGChmyWDrnG6ldGGc8gze1eRAEzpo8tF7uGcAEuRKa-1pEKhKxUxx6fbgYmijKlFgnM0VZ2E1CpWdyAaPhXKXAf2jtAONZyXMfsFPMwy7Zn8zyCCwf0xm6sOVbNfqe5y7ZaJZq9NxQdIz8QCLVodj6w-htMi_wn4Y6tLJDOg6-e7tLZs37-KF63atNCtr-TfoJ3H3XSg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Compounding+Benefits+of+Cholesterol-Lowering+Therapy+for+the+Reduction+of+Major+Cardiovascular+Events%3A+Systematic+Review+and+Meta-Analysis&rft.jtitle=Circulation+Cardiovascular+quality+and+outcomes&rft.au=Wang%2C+Nelson&rft.au=Woodward%2C+Mark&rft.au=Huffman%2C+Mark+D&rft.au=Rodgers%2C+Anthony&rft.date=2022-06-01&rft.eissn=1941-7705&rft.spage=101161CIRCOUTCOMES121008552&rft_id=info:doi/10.1161%2FCIRCOUTCOMES.121.008552&rft_id=info%3Apmid%2F35430872&rft_id=info%3Apmid%2F35430872&rft.externalDocID=35430872 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7705&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7705&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7705&client=summon |